Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Owing to higher efficiency as compared to conventional therapies such as radiation, chemo and surgery, doctors around th…
PharmaCell B.V. a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe…
PharmaCell announced today that it has entered into an agreement with Dendreon Corporation (NASDAQ: DNDN) to be the Cont…
/pressemitteilung/pdf/101775/meldung.pdf